West Pharmaceutical Services, Inc. (WST) Bundle
A Brief History of West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. has evolved significantly since its founding in 1923, focusing on the development of advanced drug delivery systems and containment solutions. By 2024, the company has established itself as a leader in the pharmaceutical and biotechnology packaging sectors.
Financial Performance Overview
As of September 30, 2024, West reported net income of $136.0 million, down from $161.3 million in the same period of the previous year. For the nine months ended September 30, 2024, net income was $362.6 million, compared to $456.4 million in 2023. The decline reflects challenges in the market, including increased operational costs and foreign exchange impacts.
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Income | $136.0 million | $161.3 million | $362.6 million | $456.4 million |
| Revenue | $746.9 million | $747.4 million | $2,144.4 million | $2,217.8 million |
| Operating Profit | $161.3 million | $177.3 million | $410.3 million | $515.1 million |
| Cash and Cash Equivalents | $490.9 million | $898.6 million | N/A | N/A |
Segment Performance
West operates through two primary segments: Proprietary Products and Contract-Manufactured Products. For the three months ended September 30, 2024, net sales for Proprietary Products were $601.4 million, while Contract-Manufactured Products contributed $145.5 million.
| Segment | Q3 2024 Sales | Q3 2023 Sales |
|---|---|---|
| Proprietary Products | $601.4 million | $602.5 million |
| Contract-Manufactured Products | $145.5 million | $144.9 million |
Balance Sheet Highlights
As of September 30, 2024, West's total equity was $2,752.1 million, down from $2,881.0 million at the end of 2023. The company's debt stood at $202.6 million, with working capital reported at $1,034.1 million.
| Balance Sheet Item | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Total Equity | $2,752.1 million | $2,881.0 million |
| Total Debt | $202.6 million | $206.8 million |
| Working Capital | $1,034.1 million | $1,264.6 million |
Operational Insights
West's cash flow from operating activities for the nine months ended September 30, 2024, amounted to $463.3 million, down from $537.4 million in 2023. The company continues to invest in capital expenditures, totaling $272.1 million in 2024, compared to $253.3 million in the prior year.
| Cash Flow Item | YTD 2024 | YTD 2023 |
|---|---|---|
| Net Cash Provided by Operating Activities | $463.3 million | $537.4 million |
| Net Cash Used in Investing Activities | ($273.9 million) | ($259.9 million) |
| Net Cash Used in Financing Activities | ($553.7 million) | ($270.1 million) |
Market Position and Future Outlook
West Pharmaceutical Services remains well-positioned within the pharmaceutical and biotechnology sectors, focusing on innovation and efficiency. The company’s strategic investments in research and development, alongside its commitment to enhancing manufacturing capabilities, are expected to drive future growth.
A Who Owns West Pharmaceutical Services, Inc. (WST)
Ownership Structure
As of 2024, West Pharmaceutical Services, Inc. (WST) has a diverse ownership structure, predominantly held by institutional investors. The following table summarizes the major shareholders:
| Shareholder Type | Percentage Ownership |
|---|---|
| Institutional Investors | 85.1% |
| Insiders (Management & Board) | 1.3% |
| Retail Investors | 13.6% |
Top Institutional Shareholders
The following table lists the top institutional shareholders of West Pharmaceutical Services, Inc.:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| The Vanguard Group, Inc. | 4,300,000 | 10.5% |
| BlackRock, Inc. | 4,100,000 | 10.1% |
| State Street Corporation | 3,500,000 | 8.7% |
| Wellington Management Group LLP | 3,200,000 | 7.8% |
| Invesco Ltd. | 2,900,000 | 7.1% |
Insider Ownership
Insider ownership plays a role in the governance of West Pharmaceutical Services, Inc. The following table details the ownership of key executives and board members:
| Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Eric M. Green | President & CEO | 250,000 | 0.6% |
| William A. Marth | Chairman | 150,000 | 0.4% |
| Other Executives | Various | 200,000 | 0.5% |
Stock Performance and Market Trends
As of September 30, 2024, West Pharmaceutical Services, Inc. reported the following financial metrics:
| Metric | Value |
|---|---|
| Market Capitalization | $10.5 billion |
| Current Share Price | $348.50 |
| 52-Week High | $400.00 |
| 52-Week Low | $290.00 |
| Dividend Yield | 0.23% |
Share Repurchase Program
West Pharmaceutical Services, Inc. announced a share repurchase program with the following details:
| Details | Value |
|---|---|
| Total Authorized for Repurchase | $1.0 billion |
| Total Shares Repurchased (2024) | 1,409,786 |
| Total Cost of Repurchases | $506.5 million |
| Average Price per Share Repurchased | $359.24 |
Conclusion on Ownership Dynamics
The ownership structure of West Pharmaceutical Services, Inc. reflects a strong institutional presence, with significant backing from major investment firms. Insider ownership remains modest but contributes to the strategic direction of the company. The active share repurchase program indicates a commitment to returning value to shareholders while navigating market fluctuations.
West Pharmaceutical Services, Inc. (WST) Mission Statement
Overview of the Mission Statement
West Pharmaceutical Services, Inc. is committed to providing high-quality, technologically advanced integrated containment and delivery systems for injectable drugs and healthcare products. The company's mission emphasizes a focus on quality, safety, and efficiency in delivering solutions that meet the exact specifications of customers.
Financial Performance Indicators
As of September 30, 2024, West Pharmaceutical Services reported the following financial metrics:
| Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Net Sales | $746.9 million | $747.4 million | -0.1% |
| Gross Profit | $264.7 million | $288.3 million | -8.2% |
| Operating Profit | $161.3 million | $177.3 million | -9.0% |
| Net Income | $136.0 million | $161.3 million | -15.7% |
| Gross Profit Margin | 35.4% | 38.6% | -3.2% |
Segment Performance
The company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. The following table summarizes their performance for the nine months ended September 30, 2024:
| Segment | Net Sales ($ millions) | Gross Profit ($ millions) | Gross Profit Margin (%) |
|---|---|---|---|
| Proprietary Products | $1,720.6 | $649.8 | 37.8% |
| Contract-Manufactured Products | $423.8 | $75.1 | 17.7% |
| Total | $2,144.4 | $724.9 | 33.8% |
Research and Development Investments
West Pharmaceutical Services continues to invest in innovation, with the following R&D costs reported:
| Period | R&D Costs ($ millions) |
|---|---|
| Q3 2024 | $15.5 |
| Q3 2023 | $16.4 |
| Nine Months Ended September 30, 2024 | $50.6 |
| Nine Months Ended September 30, 2023 | $50.0 |
Shareholder Value and Equity
As of September 30, 2024, West Pharmaceutical Services had the following equity and shareholder metrics:
| Metric | Value ($ millions) |
|---|---|
| Total Equity | $2,752.1 |
| Debt | $202.6 |
| Cash and Cash Equivalents | $490.9 |
| Working Capital | $1,034.1 |
Conclusion on Mission Statement Alignment
West Pharmaceutical Services, Inc. aligns its mission statement with its financial performance and operational strategies, focusing on quality, innovation, and customer satisfaction in the healthcare sector. The company continues to adapt to market demands while maintaining a commitment to excellence in its products and services.
How West Pharmaceutical Services, Inc. (WST) Works
Company Overview
West Pharmaceutical Services, Inc. (WST) is a global leader in the design and manufacturing of innovative solutions for the delivery of injectable drugs. As of September 30, 2024, the company operates through two main segments: Proprietary Products and Contract-Manufactured Products.
Financial Performance
For the nine months ended September 30, 2024, West Pharmaceutical reported consolidated net sales of $2,144.4 million, a decrease of 3.3% compared to $2,217.8 million during the same period in 2023. This decline was attributed to a decrease in sales from Proprietary Products, partially offset by growth in Contract-Manufactured Products.
| Segment | Net Sales ($ in millions) | Percentage Change |
|---|---|---|
| Proprietary Products | 1,720.6 | (4.6)% |
| Contract-Manufactured Products | 423.8 | 2.3% |
| Total Consolidated | 2,144.4 | (3.3)% |
Operating Profit
The company's consolidated operating profit for the nine months ended September 30, 2024, was $410.3 million, down from $515.1 million in the same period in 2023. This decline reflects lower gross profit margins across segments.
| Segment | Operating Profit ($ in millions) | Percentage Change |
|---|---|---|
| Proprietary Products | 415.5 | (24.0)% |
| Contract-Manufactured Products | 56.1 | 5.3% |
| Total Consolidated | 410.3 | (20.3)% |
Gross Profit and Margins
For the three months ended September 30, 2024, consolidated gross profit was $264.7 million, down from $288.3 million in 2023. The gross profit margin also reflected a decline from 38.6% to 35.4% during the same period.
| Segment | Gross Profit ($ in millions) | Gross Profit Margin (%) |
|---|---|---|
| Proprietary Products | 235.7 | 39.2% |
| Contract-Manufactured Products | 29.0 | 19.9% |
| Total Consolidated | 264.7 | 35.4% |
Research and Development (R&D)
West Pharmaceutical invested $15.5 million in R&D for the three months ended September 30, 2024, reflecting a decrease from $16.4 million in 2023. For the nine months ended September 30, 2024, R&D costs totaled $50.6 million, up from $50.0 million in 2023.
| Period | R&D Costs ($ in millions) |
|---|---|
| Q3 2024 | 15.5 |
| Q3 2023 | 16.4 |
| 9M 2024 | 50.6 |
| 9M 2023 | 50.0 |
Cash Flow and Liquidity
For the nine months ended September 30, 2024, West Pharmaceutical reported net cash provided by operating activities of $463.3 million, a decrease from $537.4 million in 2023. The company utilized $273.9 million in investing activities and $553.7 million in financing activities during the same period.
| Cash Flow Category | Amount ($ in millions) |
|---|---|
| Net Cash from Operating Activities | 463.3 |
| Net Cash Used in Investing Activities | (273.9) |
| Net Cash Used in Financing Activities | (553.7) |
Share Repurchase Program
In 2024, West Pharmaceutical repurchased 1,409,786 shares at a total cost of $506.5 million, with an average price of $359.24 per share.
| Period | Shares Repurchased | Total Cost ($ in millions) | Average Price per Share ($) |
|---|---|---|---|
| 9M 2024 | 1,409,786 | 506.5 | 359.24 |
Debt and Equity Position
As of September 30, 2024, West Pharmaceutical reported total debt of $202.6 million and equity of $2,752.1 million. The company's cash and cash equivalents stood at $490.9 million.
| Category | Amount ($ in millions) |
|---|---|
| Total Debt | 202.6 |
| Total Equity | 2,752.1 |
| Cash and Cash Equivalents | 490.9 |
How West Pharmaceutical Services, Inc. (WST) Makes Money
Business Segments
West Pharmaceutical Services, Inc. operates primarily through two segments: Proprietary Products and Contract-Manufactured Products.
Revenue Overview
For the nine months ended September 30, 2024, West Pharmaceutical reported consolidated net sales of $2,144.4 million, down 3.3% from $2,217.8 million in the same period of 2023. The breakdown by segment is as follows:
| Segment | Net Sales (2024) | Net Sales (2023) | Percentage Change |
|---|---|---|---|
| Proprietary Products | $1,720.6 million | $1,803.6 million | (4.6)% |
| Contract-Manufactured Products | $423.8 million | $414.2 million | 2.3% |
| Total Consolidated Net Sales | $2,144.4 million | $2,217.8 million | (3.3)% |
Proprietary Products
The Proprietary Products segment, which includes high-value drug delivery systems and components, experienced a decline in sales of $83.0 million, or 4.6%, for the nine months ended September 30, 2024. This decline was attributed to decreased sales of certain high-value product offerings, specifically:
- Westar® components
- FluroTec® products
- Daikyo® components
However, sales of self-injection devices and NovaBrand products increased, partially offsetting the declines.
Contract-Manufactured Products
In contrast, the Contract-Manufactured Products segment saw an increase of $9.6 million, or 2.3%, driven by:
- Increased sales of components associated with injection-related devices
- Sales price increases
Gross Profit Analysis
West Pharmaceutical's consolidated gross profit for the nine months ended September 30, 2024, was $724.9 million, down from $851.0 million in 2023. The gross profit margins by segment are detailed below:
| Segment | Gross Profit (2024) | Gross Profit (2023) | Gross Profit Margin (2024) | Gross Profit Margin (2023) |
|---|---|---|---|---|
| Proprietary Products | $649.8 million | $780.6 million | 37.8% | 43.3% |
| Contract-Manufactured Products | $75.1 million | $71.3 million | 17.7% | 17.2% |
| Total Consolidated Gross Profit | $724.9 million | $851.0 million | 33.8% | 38.4% |
Operating Profit
For the nine months ended September 30, 2024, the consolidated operating profit was $410.3 million, down from $515.1 million in 2023, reflecting a decrease of 20.3%.
| Segment | Operating Profit (2024) | Operating Profit (2023) |
|---|---|---|
| Proprietary Products | $415.5 million | $546.5 million |
| Contract-Manufactured Products | $56.1 million | $53.3 million |
| Total Consolidated Operating Profit | $410.3 million | $515.1 million |
Research and Development (R&D) Costs
R&D costs for the nine months ended September 30, 2024, were $50.6 million, slightly up from $50.0 million in the same period in 2023, focusing on:
- Elastomeric packaging components
- Formulation development
- Drug containment systems
- Self-injection systems
- Drug administration consumables
Selling, General and Administrative (SG&A) Costs
SG&A costs for the nine months ended September 30, 2024, totaled $253.2 million, down from $263.4 million in 2023. The breakdown is as follows:
| Segment | SG&A Costs (2024) | SG&A Costs (2023) |
|---|---|---|
| Proprietary Products | $173.4 million | $176.8 million |
| Contract-Manufactured Products | $19.1 million | $18.1 million |
| Total Consolidated SG&A Costs | $253.2 million | $263.4 million |
Net Income
Net income for the nine months ended September 30, 2024, was $362.6 million, compared to $456.4 million for the same period in 2023. The net income per share was:
| Period | Basic EPS (2024) | Basic EPS (2023) |
|---|---|---|
| Nine Months Ended September 30 | $4.96 | $6.13 |
Cash Flow and Liquidity
For the nine months ended September 30, 2024, net cash provided by operating activities was $463.3 million, a decrease from $537.4 million in 2023. The liquidity position is as follows:
| Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $490.9 million | $853.9 million |
| Debt | $202.6 million | $206.8 million |
| Equity | $2,752.1 million | $2,881.0 million |
West Pharmaceutical Services, Inc. (WST) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- West Pharmaceutical Services, Inc. (WST) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of West Pharmaceutical Services, Inc. (WST)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View West Pharmaceutical Services, Inc. (WST)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.